Pfizer: What the Print Has to Prove Today

Where our screen stands going in

Screens compliant (on our anchor standard; the faith-based screen is stricter here). A name values-conscious investors can weigh on the merits.

What the Street expects

Consensus looks for earnings of about $0.73 a share on revenue near $15.9B. Over the next twelve months analysts pencil in $2.88 of earnings per share against $0.76 over the last twelve, growth of about 279%. The median analyst target is $28 (range $25 to $36), 7% below the $30.65 share price, across 26 analysts.

How it has traded on past prints

Across the last 25 reports, the shares moved an average of +0.2% in the five sessions after the print and +0.3% over twenty. After a beat the average follow-through was +0.4%; after a miss, -1.7%. There is no reliable drift pattern: the first move has often faded, so chasing the gap has not paid.

What options are pricing

Implied volatility near 44% prices a one-week move of roughly ±6.0% (about $28.80 to $32.50). Positioning: the heaviest put open interest sits at $30 and the heaviest call open interest at $30; those strikes tend to act as magnets or walls in the days after.

Levels that matter

At $30.65 the shares sit -1% below the 52-week high of $30.44 and 30% above the low of $23.62 (103% of the way up the range). The 50-day average is $28.30, below the price. The 200-day average is $26.48, below the price.

Valuation going in

The shares trade about 14% below our fair-value estimate: a modest cushion. Our fair-value estimate is $35.62 against the current share price of $30.65. The shares trade at 39.4 times trailing earnings and 10.4 times forward earnings. Revenue is growing about 3% with net margins near 7%.

Our stance

The name clears our screen; the print tells us whether the valuation is earning its keep.

What the flow says going in

Underlying money flow reads as accumulation (21-day Chaikin Money Flow +0.15, five-day price change +3.0%, as of 2026-11-02, desk flow model).